[#item_full_content]
BOSTON–(BUSINESS WIRE)– #BiotechStartup–Newleos Therapeutics, Inc., a clinical stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, today announced the closing of an oversubscribed $93.5 million Series A financing. The financing was led by Goldman Sachs Alternatives with participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital. Newleos’ clinical-stage pipeline was in-licensed from Roche and includes multiple oral small molecules targe